Roche diabetes drug taspoglutide has hit its targets, with the pharmaceutical company claiming that Phase III clinical trials have met their primary endpoints according to most recent studies.
The Swiss diabetes drug manufacturer Roche Holding AG reportedly said on Wednesday that a diabetes treatment currently undergoing Phase III clinical trials had been a success. Roche licensed the drug from French drugmaker Ipsen in 2006 after it showed a superior reduction of HbA1c levels.
How the diabetes drug comes to market depends on final reports of its efficiency, and approval by the drug regulators around the world. A number of pharmaceutical companies are thought to have diabetes drugs currently in the pipeline.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…